Cambridge, MA-based Advanced Magnetics is touting positive results from its late-stage therapy for chronic kidney disease. The Phase III trial for the intravenous iron replacement therapy hit primary and secondary endpoints. Patients taking ferumoxytol who were not dependent on dialysis demonstrated a significant increase in hemoglobin. The trial results are being released today at the American Society of Nephrology's Renal Week in San Diego. Advanced Magnetics says that it's on track to submit an NDA in the second half of 2007.
- here's the release on the trial data